RxDoctor Payments DataLook up a doctor →

Mojun Zhu, MD

Medical Oncology · Rochester, MNNPI 1376923581

Payments from drug & device makers

$1,055,030in general payments, 2019–2025

Across 35 payments — averaging $30,144 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$314K
  • AstraZeneca$305K
  • Pfizer$164K
  • E.r. Squibb & Sons, L.L.C.$113K
  • AbbVie$66K
  • Beone Medicines USA, Inc.$61K
  • plus $32K from 2 others

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.12$313,663
AstraZeneca3$305,316
Pfizer6$163,616
E.r. Squibb & Sons, L.L.C.1$112,945
AbbVie7$66,363
Beone Medicines USA, Inc.3$61,418
Merck2$31,615
Astellas Pharma US Inc1$93

How this compares

$1,055,030 in reported general payments places this provider in the 75th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,269,010
Medicare patients
477
Services billed
73,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →